×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MESO – mesoblast limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MESO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/12
10:38 am
meso
Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]
Medium
Report
Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]
4/11
09:19 am
meso
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]
Low
Report
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]
4/10
01:39 pm
meso
Mesoblast Limited: Back From The Dead [Seeking Alpha]
Neutral
Report
Mesoblast Limited: Back From The Dead [Seeking Alpha]
4/2
11:06 pm
meso
Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/25
10:42 pm
meso
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
High
Report
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
3/25
10:34 pm
meso
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
High
Report
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
3/13
07:30 pm
meso
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Low
Report
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
3/10
07:59 pm
meso
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) [Yahoo! Finance]
High
Report
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/1
Mesoblast Submits Clinical Efficacy and Safety Data to FDA in Rolling Biologics License Application for Remestemcel-l [Yahoo! Finance News]
6.2%
6/24 Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices 6.8%
9/10 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.7%
3/30 CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS 8.5%
4/29 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 8.7%
12/17 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion 10.4%
4/8 MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY 11.4%
9/9 Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain 20.9%
4/6 FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 27.0%
4/24 83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L 91.9%
6/24 Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices 6.8%
9/10 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.7%
3/30 CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS 8.5%
4/29 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 8.7%
12/17 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion 10.4%
4/8 MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY 11.4%
9/9 Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain 20.9%
4/6 FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 27.0%
4/24 83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L 91.9%
TOP News Decliners
10/19
Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-4.2%
4/1 FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW -4.2%
4/10 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. -4.5%
8/14 Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial -4.7%
5/30 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 -5.0%
4/30 Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment -5.1%
9/18 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
2/24 Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD -8.5%
6/26 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.9%
4/27 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock. -18.4%
4/1 FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW -4.2%
4/10 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. -4.5%
8/14 Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial -4.7%
5/30 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 -5.0%
4/30 Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment -5.1%
9/18 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
2/24 Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD -8.5%
6/26 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.9%
4/27 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock. -18.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: